TABLE 14.

Benchmark dose (BMD) modelling for the critical carcinogenicity and neurotoxicity studies of TBBPA (for details of the BMD analyses, see Annex C).

Reference	Observed effect	BMD; BMDU (mg/kg bw per day)	BMDL10 (mg/kg bw per day)
Rock et al. (2019, 2nd experiment)	Latency(s) to enter light box in mice	330; 707	61.6 a
	Light box entries in mice	353; 707	77.6
	Open arms entries in mice	141; 656	3.5 a
Kim et al. (2017)	Decrease learning and memory in a passive avoidance test (day 2) in mice	79.3; 1008	10.3 a
Cope et al. (2015)	Reduction in brain parietal thickness in rats	476; 845	154
NTP (2014)	Uterus adenocarcinoma in rats	297; 1175	88.1
	Uterus adenoma, adenocarcinoma, MMMT combined in rats b	327; 1236	115
	Testis interstitial cell adenoma in rats	1226; 2045	734
	Uterine atypical endometrial hyperplasia in rats	223; 1090	41.6

^a Criteria to judge the width of the BMD credible interval not met (EFSA Scientific Committee, 2022).

^b One of 5 peer reviewers of the NTP report did not agree that MMMT should be combined with uterine epithelial tumours (NTP, 2014).